The Genomic Landscape of Actinic Keratosis

Jason Thomson1,2,3, Findlay Bewicke-Copley2,8, Chinedu Anthony Anene4,8, Abha Gulati1,3, Ai Nagano4, Karin Purdie1, Gareth J. Inman5,6, Charlotte M. Proby7, Irene M. Leigh1, Catherine A. Harwood1,3,9 and Jun Wang2,9

Actinic keratoses (AKs) are lesions of epidermal keratinocyte dysplasia and are precursors for invasive cutaneous squamous cell carcinoma (cSCC). Identifying the specific genomic alterations driving the progression from normal skin to skin with AK to skin with invasive cSCC is challenging because of the massive UVR-induced mutational burden characteristic at all stages of this progression. In this study, we report the largest AK whole-exome sequencing study to date and perform a mutational signature and candidate driver gene analysis on these lesions. We demonstrate in 37 AKs from both immunosuppressed and immunocompetent patients that there are significant similarities between AKs and cSCC in terms of mutational burden, copy number alterations, mutational signatures, and patterns of driver gene mutations. We identify 44 significantly mutated AK driver genes and confirm that these genes are similarly altered in cSCC. We identify azathioprine mutational signature in all AKs from patients exposed to the drug, providing further evidence for its role in keratinocyte carcinogenesis. cSCCs differ from AKs in having higher levels of intrasample heterogeneity. Alterations in signaling pathways also differ, with immune-related signaling and TGFβ signaling significantly more mutated in cSCC. Integrating our findings with independent gene expression datasets confirms that dysregulated TGFβ signaling may represent an important event in AK–cSCC progression.

INTRODUCTION

Actinic keratoses (AKs) are dysplastic epidermal keratinocyte lesions resulting from chronic UVR exposure. It is generally accepted that AKs are cutaneous squamous cell carcinoma (cSCC) premalignancies (Siegel et al., 2016): at least two-thirds of cSCC arise from AK, although fewer than 0.6% AK per year will progress to cSCC (Criscione et al., 2009).

Identifying genomic alterations driving AK–cSCC progression is challenging because of the high level of background mutations in keratinocytes associated with UVR exposure. AKs have an average tumor mutational burden (TMB) of 50 mutations per megabase DNA, making them among the most mutated of all human cancers (South et al., 2014).

Epigenetic alterations and immunological factors (reviewed in Bottomley et al. [2019]) add further layers of complexity in characterizing this progression.

Several molecular genetic studies have examined AK and cSCC at the levels of gene expression, chromosomal instability, and mutations in known cancer genes. These studies generally show that AK and cSCC possess similar genetic alterations with some conflict on whether AKs are more or less genomically unstable (summarized in Supplementary Table S1). However, most AK–cSCC genetic studies have used targeted techniques on fixed tissue, which have many limitations and biases. Only three previous studies have used whole-exome sequencing (WES) to study AK; these studies have included ≤10 samples and reported similar mutational spectra in AK and cSCC with frequent mutations in known cSCC tumor suppressor genes TP53, NOTCH1, NOTCH2, and FAT1 (Albibas et al., 2018; Chitsazzadeh et al., 2016; Rodriguez-Paredes et al., 2018) (Supplementary Table S2).

In this study, we present the largest WES study of AK conducted to date and include AK from both immunocompetent (IC) and immunosuppressed (IS) patients. We demonstrate that AKs are strikingly similar to cSCC at the genomic level with similar patterns of driver genes and copy number alterations. We also demonstrate mutational signature 32 in all samples from patients exposed to azathioprine, providing further evidence for its role in keratinocyte carcinogenesis at the precursor stage. By integrating our mutational pathway analysis with independent gene expression datasets, we have identified that the dysregulation of TGFβ signaling may represent a critical gatekeeper pathway resulting in AK–cSCC progression.

RESULTS

Patients and samples
A total of 37 AKs from 37 patients (median age = 70 years, range = 48–86 years) were included (Supplementary Table S1).
Table S3): 23 AKs from IS patients and 14 AKs from IC patients. WES data from cSCC samples previously analyzed for 16 of these patients were also available for comparison (Inman et al., 2018).

Mutational burden and mutational signatures

WES targeted 334,378 exons from 20,965 genes and yielded a mean coverage of \(\times 53\) with 83% of targeted bases covered by \(\times 20\) and 94% of them covered by \(\times 10\). In total, 80,511 somatic mutations (range = 12–8,326 per AK) were identified. Of these, 49,853 were nonsynonymous (range = 9–4,993 per AK) with a median of 1,676 total and 1,071 nonsynonymous mutations per AK (Figure 1a and Supplementary Tables S4 and S5). This corresponds to a mean TMB of 43.5 mutations per megabase DNA, similar to the TMB of 50 mutations per megabase DNA we previously reported in cSCC (Inman et al., 2018).

AKs from IS patients were significantly more mutated than those from IC patients when comparing total nonsynonymous mutations (median = 1,609 vs. 729 mutations, respectively; Wilcoxon test, \(P = 0.03\); Figure 1b). The results remained significant when controlled for per sample read depth (Supplementary Table S5). AKs from IS patients had a significantly higher median TMB than those from IC patients (55.9 and 22.3 mutations per megabase DNA, respectively; Wilcoxon test, \(P = 0.03\)). There was no significant difference in nonsynonymous mutation rates from AK compared with those from cSCC (median = 1,070 vs. 912; Wilcoxon test, \(P = 0.32\)).

Nine single-base substitution mutational signatures (Alexandrov et al., 2020, 2013) were identified (Figure 1c). A total of 33 AKs (89%) displayed characteristic UVR signatures (7a/b, 13–97%), mainly C > T transitions at dipyrimidine sites. A total of 20 AKs (54%) harbored variable levels (5–100%) of signature-5 mutations, and 35 AKs (95%) had low levels of signature-1 mutations (1–13%). The etiologies of signatures 5 and 1 are unknown, but both are commonly found at low levels in most cancers and are clock-like because the number of mutations correlates with age.

Signature 32 was detected in 22 AKs (59%), exclusively in patients exposed to azathioprine (Figure 1c) (Fisher’s exact test, \(P < 0.00001\), reproducing our findings in cSCC. In contrast to cSCC, the prevalence was not significantly associated with the duration of azathioprine exposure (\(r = 0.21, P = 0.33\), Supplementary Table S6).

Somatic copy number aberrations

Copy number aberrations (CNAs) and loss of heterozygosity (LOH) events were also examined (Figure 2 and Supplementary Table S7). Across our AK cohort, a median of 9% (range = 0–62%) of each AK genome was affected by CNAs (Supplementary Table S8), similar to cSCC (Wilcoxon test, \(P = 0.68\)) and independent of immune status (Wilcoxon test, \(P = 0.26\)). There was no significant correlation between mutational burden and the proportion of the genome affected by CNAs (\(r = 0.25, P = 0.13\)).

Loss of chromosome region 9p (43%), 13q (32%), 3p (24%), and 5q (24%) were the most frequent copy number losses; gain of 3q (19%), 8q (19%), 5p (16%), chromosome 20 (16%), and 1q (14%) were the most frequent gains. The most common AK CNAs correlated significantly with those of cSCC (\(r = 0.68, P = 0.003\), Supplementary Table S9).

GISTIC (Mermel et al., 2011) analysis identified 19 significantly deleted regions (\(q < 0.25\)) encompassing 859 genes, including 27 known cancer genes (Catalogue Of Somatic Mutations In Cancer database [Tate et al., 2019]). 9p21.3 was the most significantly deleted segment in AK and harbors 10 cancer genes, including CDKN2A, JAK2, and MLLT3 (Supplementary Figure S1a and Supplementary Table S10). Nine regions were significantly gained (\(q < 0.25\)) encompassing 59 genes, none known to be cancer related (Supplementary Figure S1b and Supplementary Table S11). Analysis in IC and IS subgroups did not resolve any major differences because of the limited power within each group (Supplementary Table S12).

Significantly mutated genes in AK

We used three methods to identify significantly mutated genes (SMGs): MutsigCV (\(P < 0.01\) (Lawrence et al., 2013), OncodriveFM (\(q < 0.05\) (Gonzalez-Perez et al., 2012), and OncodriveCLUST (\(q < 0.05\) (Tamborero et al., 2013). A total of 44 SMGs were confirmed by at least two methods (Figure 3a and b and Supplementary Table S13) and included the tumor suppressor genes consistently reported as mutated in cSCC ([TP53, NOTCH1, NOTCH2, FAT1, and KMT2C). HMCN1 was also altered in 50% of AKs and cSCC, consistent with previous smaller studies (Alibas et al., 2018; Durinck et al., 2011; Pickering et al., 2014). Additional SMGs included CHEK2, PBRM1, PTPRB, EBF1, STRN, and PAX3. All of them are causally implicated in other cancers. PIK3CA was the only oncogene significantly mutated using all the three methods: nonsynonymous mutations were present in 12 AKs (32%), with several of them targeting the N-terminal portion, including one nonsense and three missense mutations in the PI3K_p85B domain and a hotspot splicing mutation (\(n = 3\) just downstream of this domain (Figure 3d). Five AK mutations (including the splice-site hotspot) are known gain-of-function oncogenic mutations (Supplementary Table S14) (Chakravarty et al., 2017).

Other SMGs (IGF1R, ATAD2, ABL1, NSR1, ADAMTS9, ADAM19, KIF13B, DAB2, EIF4G3, PGR161, USP34, KCNK5, ACS51, TGFBRA1, RAB22A, XAB2, PEG10, IMPAI) have all been associated with other cancers: mutations in all of them except in RAB22A are reported in cSCC in the Catalogue Of Somatic Mutations In Cancer database (https://cancer.sanger.ac.uk/cosmic [accessed 7 January 2020]) (Tate et al., 2019). The remaining 12 SMGs (HEATR5B, KIF24, ANKRD17, AACS, MYEF2, GXYLT1, CCDC71, EPB41L2, GPS1, SLC44A3, INSIG2, and RPS2D2) have no known role in other cancers but are found mutated in cSCC in the Catalogue Of Somatic Mutations In Cancer database. The frequency of mutations in SMGs was independent of the immune status, suggesting that AKs in both groups have common drivers (Supplementary Table S15). The majority of mutational signatures present in the 44 SMGs were signature 32 (40%) and signature 7 (38%) (Figure 3c), implicating azathioprine and UV exposure as key environmental carcinogens.
IS and IC subgroup analysis using our SMG pipeline identified 23 SMGs (detected by both OncodriveFM and MutsigCV, \( P < 0.05 \) cutoff was implemented because of smaller sample sizes) in the IS group and 10 SMGs in the IC group (Supplementary Tables S16 and S17). OncodriveCLUST was unsuccessful for this analysis. TP53, NOTCH1, and NOTCH2 were the only SMGs common to IS, IC, and the combined cohort.

**Comparison between AK and cSCC SMGs**

We integrated somatic mutations and CNAs to produce a mutation OncoPrint for the 44 AK SMGs (Figure 3b) and compared this with the OncoPrint for the 22 cSCC SMGs from our previous series. TP53, NOTCH1, and NOTCH2 were the only shared SMGs, and 6 of the total 63 SMGs showed differed frequencies between AK and cSCC (Supplementary Table S18). CCDC71L (chi-square test, \( P = 0.004 \)) and STRN (\( P = 0.014 \)) were altered at higher frequency in AK, whereas LCLAT1 (\( P = 0.032 \)), HERC6 (\( P = 0.029 \)), MAP3K9 (\( P = 0.043 \)), and TMEM51 (\( P = 0.048 \)) were altered at a higher frequency in cSCC. When adjusted for multiple comparisons, none of the 63 SMGs were altered significantly between AK and cSCC.

We also compared AK SMGs with well-differentiated and moderately and/or poorly differentiated group-specific SMGs (Inman et al., 2018). There were no significant differences between SMGs in AK and those in well-differentiated cSCC, but 10 moderately and/or poorly differentiated cSCC SMGs were significantly more altered in cSCC than in AK (PRB1, TMEM51, LRP1, POLH, ACVR2A, RPLP1, ZFET1, VWF, ICAM1, and HECTD4) (Supplementary Table S18). The mutation distribution along the protein domains was similar for
AK and cSCC SMGs (Supplementary Figure S2), with the exception of the PIK3CA hotspot in AK, as described earlier.

Genes previously implicated in cSCC, such as CDKN2A and HRAS, were found altered at similar rates between our AK and cSCC cohorts (54.1% and 45% altered for CDKN2A, respectively, and 16.2% and 22.5% altered for HRAS, respectively; Supplementary Table S18).

We next compared the cancer cell fractions of non-synonymous mutations between AK and cSCC across the 63 SMGs to assess their clonality and to identify whether mutations in any genes are more clonally dominant in AK or cSCC using synonymous and untranslated region mutations as a negative control. Two genes (CACNA1C and KCNK5) showed significant evidence that nonsynonymous mutations in them were more clonally dominant in AK than in cSCC, suggesting that these genes may be under direct selection in the AK lineage (Supplementary Table S19 and Supplementary Figure S3).

Inference of clonal evolution and order of genetic changes
To assess the levels of intrasample heterogeneity, we performed clonality analyses using Expanding Ploidy and Allele-frequency on Nested Subpopulations (Andor et al., 2014), which estimates the number of clones and their proportions within each sample. A total of 31 AKs (84%) had sufficient numbers of somatic mutations (≥200) for analysis. Variation in intrasample heterogeneity was identified, with a median of four (range = 1–9) clones per AK (Figure 4a) compared with a median of six in cSCC (Wilcoxon test, P < 0.01, Figure 4b).

For each of the 44 SMGs, we assessed the order of mutation acquisition inferred from the aggregate frequencies at which they were found to be clonal or subclonal. More than 70% of mutations in 22 SMGs (TP53, NOTCH1, FAT1, ADAMTS9, CCDC71, RB1, PBRM1, ADAM19, CHEK2, KIF13B, DAB2, AB1BP, GPR161, XAB2, GPS1, IMPA1, USP34, GXYLT1, EPB41L2, PAX3, KCNK3, and INSIG2) were clonal, indicating that alterations in these genes are more likely to be early events in AK development. Compared with the 22 SMGs mentioned earlier, a relatively larger proportion of subclonal nonsynonymous mutations, implying later development, were found in the remaining 22 SMGs, although more clonal than subclonal mutations were still observed for most of them, except for PIK3CA, RAB22A, and KIF24 (Figure 4c). For the three SMGs shared by both AK and cSCC, patterns of clonality were similar, with a larger proportion of clonal mutations observed in TP53 and NOTCH1 than in NOTCH2.

Seven AKs had more than one nonsynonymous mutation in TP53, and we estimated the timing of multiple mutations in these lesions. In four samples (AK05, AK33, AK34, and AK35), all TP53 mutations appeared to be clonal and thus likely early events on the basis of clonality analysis. Two samples (AK04 and AK32) showed a mixture of early and late (i.e., subclonal) events, and one sample (AK38) exhibited both TP53 mutations as late events (Supplementary Figure S4a–d). These data suggest that although TP53 mutations are commonly observed as early events, additional mutations can occur later on in the development of AK.

Comparison of intrapatient AK with cSCC
A total of 16 AKs (43%) also had cSCC WES from the same individual (mostly from anatomically distinct sun-exposed fields) (Supplementary Table S20). There was a significant positive correlation in the mutational signature profiles of

**Figure 2. Somatic CNA and LOH events in 37 AKs.** OncoPrint of copy-gain, copy-loss, and CN LOH segments with selected known cancer driver genes annotated earlier. AK, actinic keratosis; CN, copy-neutral; CNA, copy number aberration; LOH, loss of heterozygosity.
71.4% (10 of 14) of the AK‒cSCC pairs for which data were available (Supplementary Figure S5a and b). Seven AK‒cSCC pairs had overlapping CNA segments involving a median of 20% of total CNA segments, most commonly present on chromosomes 3, 9, and 17. The direction of CNAs was largely concordant, although not statistically significant (chi-square test, \( P = 0.06 \)) (Supplementary Table S21).

**Mutational pathway analysis**

We compared significantly mutated pathways between AK and cSCC (Figure 5a and b). Many immune system signaling pathways were significantly more mutated in cSCC than in AK (TCR, Fc epsilon-RI, RIG-I-like receptor, and chemokine signaling). TGF\( \beta \), adipocytokine, GnrH, and insulin signaling were also significantly more mutated in cSCC (Figure 5a). Several metabolism pathways were differentially mutated: ether lipid, pyruvate, or \( \alpha \)-linolenic among others were significantly more mutated in cSCC (Figure 5b).

**Integration of genomic drivers, CNAs, and gene expression profiles**

We integrated the existing gene expression profiles of normal skin, AK, and cSCC to investigate the potential tumor-suppressing or -promoting roles of AK SMGs through the pattern of their expression in disease progression. We used five independent datasets (described in the Materials and Methods section). The SMG hierarchies across the datasets were broadly concordant with two main clusters observed: one consisting of SMGs upregulated in normal skin and...
progressively downregulated in AK and cSCC, and the other cluster demonstrating the reverse pattern (Figure 6a).

In AK versus normal skin, five SMGs were significantly downregulated in at least two datasets (KIF24, KCNK5, EPB41L, INSIG2, and ABI3BP), suggesting a tumor suppressor role (Figure 6a and Supplementary Figure S6a). NOTCH1 was the only significantly upregulated SMG (Figure 6b). In cSCC versus AK, IMPA1 was the sole SMG to be significantly differentially expressed in at least two datasets, being upregulated in cSCC, suggesting a tumor promoter role (Figure 6c and Supplementary Figure S6b).

Because the TGFβ signaling pathway was significantly more mutated in cSCC than in AK, we examined the expression patterns of TGFβ pathway genes in normal skin, in skin with AK, and in skin with cSCC. The datasets show two clusters of progression-dependent dysregulation of TGFβ signaling (Figure 6d). One cluster showed an upregulation of genes in the normal skin that become increasingly more downregulated, progressing from AK to cSCC, and the second cluster had the reverse pattern (Figure 6d).

We assessed the gene expression of significantly deleted and gained regions identified by our GISTIC analysis, which
revealed 55 genes in the deleted regions that were downregulated (in at least two datasets) and two genes in the gained regions that were upregulated (in at least two datasets) in AK compared with those in the normal control (Supplementary Figure S7a–c).

**DISCUSSION**

This study, the largest AK genomic dataset to date, demonstrates that AKs and cSCC are strikingly similar at the genomic level in terms of TMB, patterns of driver genes, and CNAs. The AK TMB of 43.5 mutations per megabase DNA is higher than previously reported (Hafner et al., 2010; Janus et al., 2017; Pickering et al., 2014). We also revealed 55 genes in the deleted regions that were downregulated (in at least two datasets) and two genes in the gained regions that were upregulated (in at least two datasets) in AK compared with those in the normal control (Supplementary Figure S7a–c).

**FIGURE 5. Comparison of significantly mutated KEGG pathways between AK and cSCC.** (a) Significantly mutated signaling pathways derived from OncodriveFM. (b) Significantly mutated metabolic pathways. Pathways and biological processes in the bar charts were sorted with terms significant (cutoff q = 0.05) in both groups at the top and terms significant in cSCC only at the bottom (indicated with red dashed box). AK, actinic keratoses; Act, protein kinase B; cSCC, cutaneous squamous cell carcinoma; KEGG, Kyoto Encyclopedia of Genes and Genomes; P13K, phosphoinositide 3-kinase; SCC, squamous cell carcinoma.

sun-exposed skin (Martincorena et al., 2015). However, CDKN2A is not mutated in the normal skin, and we previously postulated that it may have a gatekeeper role in cSCC (Inman et al., 2018). CDKN2A was not identified as an SMG, but the loss of 9p21.3—a CDKN2A gene locus—was identified as the most significantly deleted CNA, and there was no significant difference in the frequency of deletion in AK compared with that in cSCC (54% vs. 45%, respectively, chi-square test, P = 0.43, Supplementary Table S18), suggesting that this deletion is an early event and may play an important role in AK pathogenesis. The oncogene PIK3CA was significantly altered in almost half of all AKs and cSCCs, a higher frequency than seen in previous cSCC studies (Hafner et al., 2010; Janus et al., 2017; Pickering et al., 2014). We also identified a hotspot activating splice-site mutation in three AKs. Activating mutations in PIK3CA result in the activation of the phosphoinositide 3-kinase/protein kinase B/mTOR pathway, which is commonly seen in other organs’ squamous cell carcinomas (Vivanco and Sawyers, 2002).

Although we identified 16.2% AKs with alterations (all CNAs, four losses, and two gains) in HRAS, no single-nucleotide variants were detected in our cohort. This aligns with other studies where oncogenic RAS mutations are very rare in UV-exposed skin and AKs and/or squamous cell carcinoma in situ (Chitsazzadeh et al., 2016; Martincorena et al., 2015; Zheng et al., 2020). In our cSCC cohort, 22.5% harbored alterations in HRAS, and this was identified as a cSCC SMG, but only three cSCCs were predicted to have activating mutations. This provides further evidence that human AKs and cSCCs are biologically distinct from murine 7,12-dimethylbenz[a]anthracene/
12-O-tetradecanoylephorbol-13-acetate model lesions where activating HRAS mutations are common (Huang and Balmain, 2014). Nevertheless, activating RAS mutations still appear to play a functional role in cSCC development for a subset of cSCC tumors rather than in AK–cSCC in situ development.

Figure 6. Expression profiles of SMGs in the five independent gene expression datasets. (a) Expression heatmap of 37 SMGs across NSE skin, sun-exposed skin, AK, and cSCC samples from the Lambert dataset. LogFC of pairwise comparisons of (b) AK versus NSE and (c) SCC versus AK across the five datasets (Lambert, GSE42677, GSE84293, GSE2503, and GSE32628). Normal skin: NSE skin, sun-exposed skin, AK, and SCC. Significant genes with the same direction in 2 of 5 datasets were highlighted in blue (downregulated) or in red (upregulated). Within b and c, the blue color indicates the downregulation in AK or SCC compared with the downregulation in NSE or AK, respectively, and the red color indicates the upregulation in AK or SCC relative to that in NSE or AK, respectively. (d) Expression heatmap of TGFβ signaling genes that were expressed across NSE skin, sun-exposed skin, AK, and cSCC samples from the Lambert dataset. AK, actinic keratosis; cSCC, cutaneous squamous cell carcinoma; LogFC, Log2 fold change; NSE, non–sun-exposed; SCC, squamous cell carcinoma; SMG, significantly mutated gene.
**HMCN1** was identified as an SMG, being altered in 19 AKs (51%). Although not a confirmed cancer gene, its role warrants further investigation because it is frequently mutated in cSCC ([Durinck et al., 2011; Pickering et al., 2014] and AKs [Alibbias et al., 2018]). It is postulated to be involved in cancer cell invasion and metastasis ([Timpl et al., 2003]) through its function as an extracellular matrix protein.

We show that AKs have the same levels of genomic instability as cSCC with many shared CNAs between them, notably loss of 9p, chromosome 13, and 5q. Apart from an early study that suggested that AKs have more LOH than cSCC ([Rehman et al., 1996]), our findings are contrary to those of more recent studies that found that AKs have relatively few CNAs ([García-Diez et al., 2019; Hameetman et al., 2013]). However, most studies agree on the most common sites of chromosomal instability, with 9p loss—the region where **CDKN2A** is located—ubiquitous among AK studies ([Ashton et al., 2003; García-Diez et al., 2019; Kanelloú et al., 2008; Rehman et al., 1996]).

Interrogating published expression datasets against our SMG list found **KIF24**, **KCNK5**, **EPB41L2**, and **ABI3BP** downregulated in AK compared with those in the normal skin, suggesting tumor suppressor roles. **ABI3BP** was significantly downregulated in cSCC compared with that in the normal skin in one previous study ([Prasad et al., 2014]) and similarly downregulated in the esophagus with squamous cell carcinoma compared with that in the normal esophagus ([Jiang et al., 2018]). It is a tumor suppressor and promoter roles in different cancer types and possessing the majority of genomic alterations present in cSCC. Significant molecular alterations, which we have uncovered and which may contribute to evolution from AK to cSCC, include alterations in key signaling pathways, particularly in TGFB and immune system signaling; mutations in specific genes, including **ABI3BP** and **IMPA1**; and differences in intrasample heterogeneity. These will be the focus of future investigations of the molecular pathogenesis of AK progression.

---

**MATERIALS AND METHODS**

**Collection of patient samples and clinical data**

The 4 mm punch biopsies of AK diagnosed clinically and confirmed histologically were obtained from participants after written informed consent was obtained. Processing of AK and venous blood for matched germline DNA and clinical data collection was done as previously described ([Inman et al., 2018]). The study was approved by the East of Scotland Research Ethics Service (reference: 08/S1401/69) and the East London and City Health Authority Local Ethics Committee and conducted according to the Declaration of Helsinki Principles.

**DNA extraction and genetic analysis**

DNA extraction and genetic analysis were performed as previously described ([Inman et al., 2018]).

**WES data processing, somatic variant calling, annotation, and visualization**

WES data were analyzed and annotated using our established pipeline ([Inman et al., 2018]). MafTools was used to summarize, visualize, and compare AK and cSCC Mutation Annotation Format files and to make lollipop plots of gene mutation distributions ([Mayakonda et al., 2018]). Mutation signatures across the exomes were identified on the basis of the nonnegative matrix factorization approach previously described ([Alexandrov et al., 2020, 2013]) using the Catalogue Of Somatic Mutations In Cancer mutational signatures.
Identification of CNA and LOH using WES data
Analyses for CNA and LOH events from WES data were based on a combinational approach previously described (Okosun et al., 2016; Tawana et al., 2015). Genes targeted by copy-gain, copy-loss, and copy-neutral LOH in each sample were identified. Thresholds for CNA calls were fully described in our previous study (Inman et al., 2018).

Tumor subpopulation identification and clonality analysis
Expanding Ploidy and Allele-frequency on Nested Subpopulations (Andor et al., 2014) was used to estimate clonal expansions and cellular frequency of each clonal and subclonal population as previously described (Inman et al., 2018). Tumor purity was also estimated on the basis of the cellular frequency of the dominant clone. All somatic variants were assigned to their nested clones.

Gene expression data analysis and integration
Five sets of expression data of patient samples were selected (same as our cSCC study) and downloaded from Gene Expression Omnibus: GSE45216 (Lambert et al., 2014), GSE42677 (Mitsu et al., 2014), GSE84293 (Chitsazzadeh et al., 2016), GSE2503 (Nindel et al., 2006; Padilla et al., 2010), and GSE32628 (Hameeteen et al., 2013). Differential expression analyses between different groups were performed using limma R package (Ritchie et al., 2015). The Differential expression genes were defined at adjusted P ≤ 0.1.

Data availability statement
Datasets related to this article can be found at https://www.ebi.ac.uk/ega/search/site/EGAS00001004243, deposited at the European Genome-phenome Archive, which is hosted by European Bioinformatics Institute (Cambridge, United Kingdom) and the Centre for Genomic Regulation (Barcelona, Spain) (Lappalainen et al., 2015).

ORCIDs
Jason Thomson: https://orcid.org/0000-0002-6644-0979
Findlay Bewicke-Copley: https://orcid.org/0000-0003-1292-7965
Chineedu Anthony Anene: https://orcid.org/0000-0002-3591-3358
Abha Gulati: https://orcid.org/0000-0003-1970-6145
Karin Purdie: https://orcid.org/0000-0001-7928-0743
Gareth J. Inman: https://orcid.org/0000-0002-6264-4253
Charlotte M. Proby: https://orcid.org/0000-0002-3292-4836
Irene M. Leigh: https://orcid.org/0000-0001-8536-6439
Catherine A. Harwood: https://orcid.org/0000-0002-1375-0965
Jun Wang: https://orcid.org/0000-0003-2509-9599

CONFLICT OF INTEREST
CAH reports receiving speaker honoraria from Sanofi/Regeneron and Merck and advisory board honoraria from Roche, Leo Pharma, and Pellepharm. CAH acts as the clinical trial investigator in Novartis, Principia, Leo Pharma, Pellepharm. CAH reports receiving research funding for an investigator-led clinical trial from Meda AB. The remaining authors state no conflict of interest.

ACKNOWLEDGMENTS
This work was supported by Cancer Research UK program grant (reference 13044) and a Barts Charity small project grant (reference MGU0394, awarded to JT), CAA is funded by the Barts Charity project grant (reference MRD&U0003). JW, FBC, and CAA also acknowledge support from the Cancer Research UK Centre of Excellence Award to Barts Cancer Centre (London, United Kingdom) (reference C16420/A18066). GJi acknowledges support from Cancer Research UK Beatson Institute (Glasgow, United Kingdom) core grant.

AUTHOR CONTRIBUTIONS
Conceptualization: JT, AG, GJi, KP, CMP, IML, CAH, JW; Data Curation: JT, JW; Formal Analysis: JT, JW, CAA, AN, FBC; Funding Acquisition: CAA, JW, JT, IML; Investigation: JT, AG, JW, KP, AN, CAA, FBC, CAH; Methodology: JT, JW, KP, AG, CAH, IML, CMP, GJi; Project Administration: JW, CAH; Resources: JW, CAH; Supervision: JW, CAH; Validation: JW; Visualization: JT, CAA, FBC; Writing — Original Draft Preparation: JT, JW, CAH; Writing — Review and Editing: JT, CAA, FBC, AG, AN, KP, CMP, IML, GJi, CAH, JW

SUPPLEMENTARY MATERIALS
Supplementary material is linked to the online version of the paper at www.jidonline.org, and at https://doi.org/10.1016/j.jid.2020.12.024.

REFERENCES
Alibas AA, Rose-Zerilli MJ, Lai C, Pengelly RJ, Lockett GA, Theaker J, et al. Subclonal evolution of cancer-related gene mutations in p53 immuno-positive patches in human skin. J Invest Dermatol 2018;138:189–98.
Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AWT, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature 2020;578:94–101.
Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. Deciphering signatures of mutational processes operative in human cancer. Cell Rep 2013;3:246–59.
Andor N, Harness JV, Müller S, Mewes HW, Petritsch C. EXPANDS: expanding ploidy and allele frequency on nested subpopulations. Bioinformatics 2014;30:50–60.
Ashton KJ, Weinstein SR, Maguire DJ, Griffiths LR. Chromosomal aberrations in squamous cell carcinoma and solar keratoses revealed by comparative genomic hybridization. Arch Dermatol 2003;139:876–82.
Bottomley MJ, Thomson J, Harwood C, Leigh I. The role of the immune system in cutaneous squamous cell carcinoma. Int J Mol Sci 2019;20:2009.
Cammarperi P, Rose AM, Vincent DF, Wang J, Nagano A, Libertino S, et al. Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma. Nat Commun 2016;7:12493.
Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol 2017;2017:1–16.
Chitsazzadeh V, Coařa C, Drummond JA, Nguyen T, Joseph A, Chilukuri S, et al. Cross-species identification of genomic drivers of squamous cell carcinoma development across preeoplastic intermediates. Nat Commun 2016;7:12601.
Crisconde VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention trial. Cancer 2009;115:2523–30.
Durinc S, Ho C, Wang NJ, Liao W, Jakkula LR, Collisson EA, et al. Temporal dissection of tumorigenesis in primary cancers. Cancer Discov 2011;1:137–43.
García-Diez J, Hernández-Muñoz I, Hernández-Ruiz E, Nonell L, Puigdecanet E, Bódal-Orruella M, et al. Transcriptome and cytogenetic profiling analysis of matched in situ/invasive cutaneous squamous cell carcinomas from immunocompetent patients. Genes Chromosomes Cancer 2019;58:164–74.
Gonzalez-Perez A, Deu-Pons J, Lopez-Bigas N. Improving the prediction of cancer genomics in high-risk cutaneous squamous cell carcinoma. PLoS Med 2011;8:e1001078.
Hafner C, Landthaler M, Vogt T. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations. Exp Dermatol 2010;19:e222–7.
Hameeteen L, Commandeur S, Bavinck JN, Wisgerhof HC, de Gruijl FR, Puigdecanet E, Bodalo-Torruella M, et al. Transcriptome and cytogenetic profiling analysis of matched in situ/invasive cutaneous squamous cell carcinomas from immunocompetent patients. Genes Chromosomes Cancer 2019;58:164–74.
Hodgkinson CP, Naidoo V, Patti KG, Gomez JA, Schmeckpeper J, Zhang Z, et al. The repertoire of mutational signatures in human cancer. Nature 2020;578:94–101.
Han G, Lu SL, Li AG, He W, Corless CL, Kulesz-Martin M, et al. Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J Clin Invest 2005;115:1714–23.
Hervás-Marin D, Higgins F, Sanmartin O, López-Guerrero JA, Bañó MC, Igual JC, et al. Genome wide DNA methylation profiling identifies specific epigenetic features in high-risk cutaneous squamous cell carcinoma. PLoS One 2019;14:e0223341.
Hodgkinson CP, Naidoo V, Patti KG, Gomez JA, Schmeckpeper J, Zhang Z, et al. Abi3bp is a multifunctional autocrine/paracrine factor that regulates mesenchymal stem cell biology. Stem Cells 2013;31:1669–82.
Huang PY, Balmain A. Modeling cutaneous squamous carcinoma development in the mouse. Cold Spring Harb Perspect Med 2014;4:a013623.
Inman GJ, Wang J, Nagano A, Alexandrov LB, Purdie KJ, Taylor RG, et al. The genomic landscape of cutaneous SCC reveals drivers and a novel aza-hithioprime associated mutational signature. Nat Commun 2018;9:3667.

Janus JM, O’Shaughnessy RFL, Harwood CA, Maffucci T. Phosphoinositide 3-kinase-dependent signalling pathways in cutaneous squamous cell carcinomas. Cancers 2017;9:86.

Jiang S, Zhang Q, Su Y, Pan L. Network-based differential analysis to identify molecular features of tumorigenesis for esophageal squamous carcinoma. Molecules 2018;23:88.

Kanellou P, Zaravinos A, Zioga M, Stratigos A, Baritaki S, Soufia G, et al. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratoses. Cancer Lett 2008;264:145–61.

Lambert SR, Mladkova N, Gulati A, Hamoudi R, Purdie K, Cerio R, et al. Key differences identified between actinic keratosis and cutaneous squamous cell carcinoma by transcriptome profiling. Br J Cancer 2014;110:520–9.

Lappalainen I, Almeida-King J, Kurnamuri V, Senf A, Spalding JD, Ur-Rehman S, et al. The European Genome-phenome Archive of human data consented for biomedical research. Nat Genet 2015;47:692–5.

Latini FR, Hemery JP, Oler G, Riggins GJ, Cerutti JM. Re-expression of ABI3-binding protein suppresses thyroid tumor growth by promoting senescence and inhibiting invasion. Endocr Relat Cancer 2008;15:787–99.

Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214–8.

Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S, et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma related to distinct cells of origin. Nat Commun 2018;9:577.

Siegel JA, Korgavkar K, Weinstock MA. Current perspective on actinic keratoses: a review. Br J Dermatol 2016;177:350–8.

South AP, Purdie KJ, Watt SA, Haldenby S, den Breeems NY, Dimon M, et al. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. J Invest Dermatol 2014;134:2630–8.

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Supplementary Figure S1. Significantly (a) deleted and (b) gained regions across the 33 AK samples based on GISTIC2.0. Four samples were excluded from the analysis because they have too few CNA segments. AK, actinic keratosis; CNA, copy number aberration.
Supplementary Figure S2. Lollipop plots of key AK and cSCC driver genes showing the type and distribution patterns of nonsynonymous mutations between AK and cSCC. aa, amino acid; AK, actinic keratosis; cSCC, cutaneous squamous cell carcinoma; Del, deletion; Ins, insertion.
Supplementary Figure S3. Boxplots of CCFs of synonymous and nonsynonymous mutations of SMGs between AK and cSCC, highlighting that two genes had more clonal nonsynonymous mutations in AK than in (a) CACNA1C and (b) KCNK5, using synonymous mutations as the negative control. AK, actinic keratosis; CCF, cancer cell fraction; SMG, significantly mutated gene; SCC, squamous cell carcinoma.
Supplementary Figure S4. TP53 clonality analysis. (a) Bar chart of the number of clonal and subclonal TP53 mutations in selected AK samples with >1 nonsynonymous TP53 mutation. (b–d) Line graphs of CCF of TP53 nonsynonymous mutations for (b) AK05, AK33, AK34, AK38, (c) AK32, and (d) AK04. AK, actinic keratosis; CCF, cancer cell fraction.
Supplementary Figure S5. Correlation of mutation signatures between matched AK and cSCC pairs. (a) Mutation signature compositions in matched AK and cSCC pairs. Two pairs (AK03–MD03 and AK29–WD08) were not included because the cSCC did not have mutational signature data. P-values from Pearson correlation statistic. Signature 32 = azathioprine signature, and signature 7 = UVR signature. (b) Table of Pearson correlation analysis. AK, actinic keratosis; cSCC, cutaneous squamous cell carcinoma; MD, moderately differentiated; WD, well-differentiated.
Supplementary Figure S6. Box and whisker plot comparing (a) ABI3BP with (b) IMPA1 mRNA expression across NSE skin, sun-exposed skin, AK, and cSCC, depicting the statistics for between-group comparisons. ns and significant at **$P < 0.01$ and ***$P < 0.001$. AK, actinic keratosis; cSCC, cutaneous squamous cell carcinoma; ns, not significant; NSE, non-sun-exposed; SCC, squamous cell carcinoma.
Supplementary Figure S7. Expression profiles of genes significantly gained (red) or deleted (black) in AK. (a) Expression heatmap of significantly gained, upregulated genes (n = 2, red) and deleted, downregulated genes (n = 52, black) in the AK versus those in the normal skin that were also expressed across normal skin, AK, and in situ and invasive cSCC samples from the GSE42677. (b) Venn diagram of overlap across the five gene expression datasets of significantly deleted and downregulated genes in AK versus those in the normal skin. (c) LogFC of significant genes with the same direction in 2 of 5 datasets in pairwise comparisons of AK with normal skin across the five datasets (Lambert, GSE42677, GSE84293, GSE2503, and GSE32628). The blue color indicates the downregulation in AK compared with that in the normal skin, and the red color indicates the upregulation in AK relative to that in the normal skin. AK, actinic keratosis; cSCC, cutaneous squamous cell carcinoma; LogFC, Log2 fold change.